Ontario Teachers Pension Plan Board Reduces Holdings in Inari Medical, Inc. (NASDAQ:NARI)

Ontario Teachers Pension Plan Board cut its stake in shares of Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 75.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,047 shares of the company's stock after selling 43,709 shares during the period. Ontario Teachers Pension Plan Board's holdings in Inari Medical were worth $579,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in Inari Medical by 164.7% in the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company's stock valued at $34,000 after acquiring an additional 438 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Inari Medical by 83.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company's stock worth $46,000 after purchasing an additional 435 shares during the last quarter. Covestor Ltd raised its stake in shares of Inari Medical by 30.2% during the 1st quarter. Covestor Ltd now owns 1,619 shares of the company's stock worth $78,000 after purchasing an additional 376 shares in the last quarter. KBC Group NV boosted its holdings in shares of Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company's stock valued at $73,000 after buying an additional 498 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. grew its stake in shares of Inari Medical by 39.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company's stock valued at $89,000 after buying an additional 522 shares in the last quarter. Institutional investors own 90.98% of the company's stock.

Inari Medical Price Performance

Shares of NARI traded down $0.09 during mid-day trading on Friday, hitting $49.66. The stock had a trading volume of 608,816 shares, compared to its average volume of 982,105. The firm has a market cap of $2.91 billion, a P/E ratio of -37.07 and a beta of 0.96. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $67.13. The business has a fifty day moving average price of $45.60 and a 200-day moving average price of $47.21.

Insider Activity at Inari Medical

In other Inari Medical news, CEO Andrew Hykes sold 3,000 shares of the stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the transaction, the chief executive officer now owns 445,310 shares of the company's stock, valued at approximately $22,265,500. This represents a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William Hoffman sold 60,000 shares of the business's stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $51.16, for a total value of $3,069,600.00. Following the sale, the director now directly owns 501,233 shares of the company's stock, valued at $25,643,080.28. This represents a 10.69 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 186,000 shares of company stock valued at $8,990,990. Corporate insiders own 10.60% of the company's stock.

Analyst Ratings Changes

NARI has been the topic of several recent analyst reports. Truist Financial boosted their price objective on shares of Inari Medical from $46.00 to $50.00 and gave the stock a "hold" rating in a research note on Tuesday, October 29th. Leerink Partnrs upgraded Inari Medical to a "hold" rating in a report on Tuesday, September 3rd. William Blair started coverage on Inari Medical in a research note on Thursday, July 25th. They set an "outperform" rating for the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Inari Medical in a research note on Tuesday, October 29th. Finally, Canaccord Genuity Group boosted their target price on shares of Inari Medical from $71.00 to $74.00 and gave the company a "buy" rating in a research report on Tuesday, October 29th. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, Inari Medical presently has an average rating of "Hold" and an average price target of $58.89.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.